
AstraZeneca rated 'Strong Buy' after strong Q1 2026 revenue growth and promising drug data.
AstraZeneca received a 'Strong Buy' rating following robust revenue growth in Q1 2026, driven by 16% and 15% increases in its Oncology and Rare Disease segments, respectively. Key drugs IMFINZI and ULTOMIRIS showed positive phase 3 trial results, ope...



